Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells.
Cetuximab is a chimeric mouse-human monoclonal antibody that targets the human epidermal growth factor receptor (EGFR). However, EGFR expression determined by immunohistochemistry does not predict clinical outcomes of colorectal cancer (CRC) patients treated with cetuximab. Therefore, we evaluated t...
Main Authors: | Kohei Shigeta, Tetsu Hayashida, Yoshinori Hoshino, Koji Okabayashi, Takashi Endo, Yoshiyuki Ishii, Hirotoshi Hasegawa, Yuko Kitagawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3688890?pdf=render |
Similar Items
-
Needlescopic versus conventional laparoscopic surgery for colorectal cancer ~a comparative study~
by: Masashi Tsuruta, et al.
Published: (2017-04-01) -
Metformin inhibits the development and metastasis of colorectal cancer
by: Hasegawa, H., et al.
Published: (2022) -
Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab
by: Zeuli Massimo, et al.
Published: (2010-04-01) -
Evolving role of cetuximab in the treatment of colorectal cancer
by: Gunter Schuch, et al.
Published: (2009-07-01) -
Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
by: Kohei Shitara, et al.
Published: (2010-07-01)